CA2250076A1 - Procede de pronostic de l'evolution d'une hepatite b - Google Patents

Procede de pronostic de l'evolution d'une hepatite b Download PDF

Info

Publication number
CA2250076A1
CA2250076A1 CA 2250076 CA2250076A CA2250076A1 CA 2250076 A1 CA2250076 A1 CA 2250076A1 CA 2250076 CA2250076 CA 2250076 CA 2250076 A CA2250076 A CA 2250076A CA 2250076 A1 CA2250076 A1 CA 2250076A1
Authority
CA
Canada
Prior art keywords
hbeag
infection
antibodies
hbe
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2250076
Other languages
English (en)
Inventor
Wilhelmina Petronella Paulij
Markus Hendrikus Van Roosmalen
Rudolf Arnold Heijtink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2250076A1 publication Critical patent/CA2250076A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne le pronostic du développement de l'hépatite B. Le procédé de l'invention convient également au suivi d'une thérapie antivirale à base par exemple de composés antiviraux tels que l'interféron .alpha.. L'invention repose sur la découverte que la présence de biomolécules aptes à former des complexes avec le HBeAg constitue un indicateur de pronostic du développement ultérieure de la phase aiguë de l'hépatite B. On a découvert la présence ou l'absence de ces biomolécules spécifiques ou de complexes de ces biomolécules et de HBeAg pendant la phase aiguë de la maladie, permet de prévoir si le patient guérira et se débarrassera du virus après la phase aiguë ou s'il développera une infection chronique. La présente invention fait donc intervenir un dosage permettant de détecter des complexes circulants comprenant les biomolécules spécifiques liées au HBeAg, et ce, en utilisant un procédé permettant de prévoir l'évolution de la maladie chez des patients atteints d'hépatite B en phase aiguë. L'invention concerne également un procédé de pronostic du développement de l'hépatite B qui convient également au suivi d'une thérapie à base d'agents antiviraux et qui permet d'indiquer l'effet produit par une telle thérapie.
CA 2250076 1996-03-19 1997-03-17 Procede de pronostic de l'evolution d'une hepatite b Abandoned CA2250076A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96200758.9 1996-03-19
EP96200758 1996-03-19

Publications (1)

Publication Number Publication Date
CA2250076A1 true CA2250076A1 (fr) 1997-09-25

Family

ID=8223798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2250076 Abandoned CA2250076A1 (fr) 1996-03-19 1997-03-17 Procede de pronostic de l'evolution d'une hepatite b

Country Status (6)

Country Link
EP (1) EP0888551A1 (fr)
JP (1) JP2000506735A (fr)
KR (1) KR20000064637A (fr)
AU (1) AU2028297A (fr)
CA (1) CA2250076A1 (fr)
WO (1) WO1997035204A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374812T3 (es) 2000-08-11 2012-02-22 Advanced Life Science Institute, Inc. Método para detectar o medir vhb.
US20090280474A1 (en) * 2008-05-08 2009-11-12 Abbott Laboratories Method for detecting a virus
US20130084584A1 (en) * 2010-03-31 2013-04-04 Anna Blom Method to detect tissue degradation leading to inflammation
EP3655430A1 (fr) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anticorps et procédés de diagnostic et de traitement d'infection par le virus de l'hépatite b
EP3788377A1 (fr) * 2018-05-04 2021-03-10 Abbott Laboratories Méthodes et produits de diagnostic, de pronostic et de thérapie du vhb
CN111879923A (zh) * 2020-08-06 2020-11-03 深圳科隆生物新材料有限公司 一种可消除hama效应的试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1123733A (fr) * 1977-12-14 1982-05-18 Isa K. Mushahwar Antigene de l'hepatite-b et anticorps sous forme insoluble
AU8746582A (en) * 1981-09-02 1983-03-10 Biogen N.V. Hepatitis b virus e type antigen
US4459359A (en) * 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
WO1994008597A1 (fr) * 1992-10-14 1994-04-28 The Scripps Research Institute Procede de detection de complexes immuns specifiques d'antigenes
JPH06321991A (ja) * 1993-05-14 1994-11-22 Mitsubishi Kasei Corp Ｂ型肝炎ウイルス由来のポリペプチドおよびそれをコードする遺伝子
US5726011A (en) * 1994-03-31 1998-03-10 Virginia Commonwealth University Method for diagnosing chronic hepatitis B virus infection
JP3401690B2 (ja) * 1994-07-11 2003-04-28 富士レビオ株式会社 新規ポリペプチド及びそれを用いた抗Ｂ型肝炎ウイルスｅ抗原抗体の免疫測定方法

Also Published As

Publication number Publication date
KR20000064637A (ko) 2000-11-06
JP2000506735A (ja) 2000-06-06
EP0888551A1 (fr) 1999-01-07
AU2028297A (en) 1997-10-10
WO1997035204A1 (fr) 1997-09-25

Similar Documents

Publication Publication Date Title
Bhatnagar et al. Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant.
KR0181343B1 (ko) 간염 씨 바이러스에 대한 항체 검출용 합성 항원
EP0152477B1 (fr) Anticorps monoclonaux d'oncoproteines induits par des polypeptides
US5563247A (en) Monoclonal antibodies to oncoproteins and methods of making monoclonal antibodies
US5229491A (en) Peptides immunochemically reactive with antibodies directed against hepatitis non-a, non-b virus
KR930004055B1 (ko) 펩티드 및 그의 용도
JPH045653B2 (fr)
EP0291180A1 (fr) Essai pour l'anticorps anti-pré-S
Jolivet‐Reynaud et al. Localization of hepatitis B surface antigen epitopes present on variants and specifically recognised by anti‐hepatitis B surface antigen monoclonal antibodies
Petit et al. A monoclonal antibody specific for the hepatocyte receptor binding site on hepatitis B virus
WO1997040164A1 (fr) Anticorps monoclonaux contre l'hepatite b
CA2250076A1 (fr) Procede de pronostic de l'evolution d'une hepatite b
Budkowska et al. A monoclonal antibody enzyme immunoassay for the detection of epitopes encoded by the pre-S2 region of the hepatitis B virus genome
CA2041772A1 (fr) Anticorps monoclonaux diriges contre la polypeptide pres2 et pres1 de l'enveloppe virale de l'hepatite b
KR0127148B1 (ko) 발현 마커(marker)로서 HBxAg를 함유하는 SV40발현 벡터
US6682896B1 (en) Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof
EP0993470B1 (fr) Anticorps et autres molecules de liaison specifiques les antigenes viraux de l'hepatite b
EP0525910A1 (fr) Peptide non-A, non-B
JPH09249699A (ja) 抗ヒトｐｉｖｋａ−ｉｉモノクローナル抗体、該抗体を産生するハイブリドーマ、該抗体を用いた測定試薬及び測定方法
JPS58150518A (ja) Ｂ型肝炎ウイルスのための免疫学的組成物及び方法
US5985541A (en) Peptide capable of being recognized by antibodies recognizing the C33 antigen of hepatitis C virus
US5204446A (en) Polypeptide having immunoreactivity with antibody specific to hepatitis b virus
EP0501557B1 (fr) Peptides, immunochimiquement réactives avec anticorps contre le virus de l'hépatite non-A, non-B
JPH05320192A (ja) 非ａ非ｂ型肝炎ウイルスに対する抗体に免疫化学反応性を示すペプチド
JPH05230097A (ja) Ｂ型肝炎ウイルスのＨＢｃ抗原由来の合成ペプチド、このウイルスによる感染を検出すること及び抗Ｂ型肝炎ワクチンのための該ペプチドの使用

Legal Events

Date Code Title Description
FZDE Dead